Q4 Earnings Estimate for Metagenomi Issued By HC Wainwright

Metagenomi, Inc. (NASDAQ:MGX) – Investment analysts at HC Wainwright raised their Q4 2024 earnings estimates for Metagenomi in a research report issued on Thursday, November 21st. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.52) per share for the quarter, up from their prior forecast of ($0.69). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Metagenomi’s current full-year earnings is ($2.68) per share. HC Wainwright also issued estimates for Metagenomi’s Q1 2025 earnings at ($0.56) EPS, Q2 2025 earnings at ($0.59) EPS, Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.69) EPS and FY2025 earnings at ($2.48) EPS.

Several other research analysts have also recently weighed in on the company. BMO Capital Markets decreased their price target on Metagenomi from $22.00 to $17.00 and set an “outperform” rating for the company in a research note on Thursday, August 15th. Chardan Capital reissued a “buy” rating and issued a $15.00 target price on shares of Metagenomi in a research report on Wednesday, November 20th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $15.50.

Metagenomi Price Performance

MGX stock opened at $2.01 on Monday. The stock’s 50 day simple moving average is $2.03 and its 200 day simple moving average is $3.60. Metagenomi has a 12-month low of $1.61 and a 12-month high of $12.74.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of MGX. Rhumbline Advisers purchased a new stake in shares of Metagenomi during the 2nd quarter valued at about $26,000. BNP Paribas Financial Markets grew its position in Metagenomi by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock valued at $28,000 after buying an additional 7,256 shares during the period. Virtu Financial LLC purchased a new stake in Metagenomi during the third quarter valued at approximately $33,000. XTX Topco Ltd bought a new position in Metagenomi in the second quarter worth approximately $66,000. Finally, Green Alpha Advisors LLC bought a new position in Metagenomi in the third quarter worth approximately $69,000.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.